International Journal of Hematology and Oncology 2019, Vol 29, Num 1 Page(s): 104-109
REPORTS FROM FORTY-FIRST AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)-2005 MEETING: TRASTUZUMAB USE IN THE ADJUVANT TREATMENT OF BREAST CANCER

Kadri ALTUNDAĞ1, Banu ARUN2

1Hacettepe Tıp Fakültesi, Onkoloji Enstitüsü, Medikal Onkoloji Bölümü, Ankara
2The University of Texas, M.D. Anderson Cancer Center, Breast Medical Oncology, Houston, Texas, USA

Keywords: Breast Cancer, Trastuzumab, Adjuvant
Trastuzumab (Herceptin), a humanized monoclonal antibody specific for HER-2, has been used successfully in the management of metastatic HER-2-overexpressing breast cancers. The clear efficacy of trastuzumab against HER-2- overexpressing metastatic breast cancer has led to a rationale in testing its adjuvant role in the management of early breast cancer. We summarize three important studies about the adjuvant use of trastuzumab in breast cancer patients presented in 41. ASCO annual meeting 2005.